Millie: Search Results

Patients on both arms were assessed at baseline, 6, 12, 24, and 60 months through the Expanded Prostate Index Composite (EPIC) for bowel, urinary, sexual and hormone domains, the Hopkins Symptom Checklist (HSCL) measuring anxiety and depression, and the Eq5D measuring QOL.

Professor Karim Fizazi and Professor Eleni Efstathiou set the scene in current care and discuss the treatment options available for hormone-sensitive metastatic prostate cancer, highlighting the unmet need in recurrent metastatic disease. New updates to...

Professor Karim Fizazi chairs a discussion with Professors Eleni Efstathiou, Nicholas Mottet, and Boris Hadaschek on the latest data presented at ASCO GU 2019 in San Francisco, specifically focused on patients with non-metastatic CRPC. The group...

Dr Nicholas van As speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about analysis of acute toxicity from the randomised phase III PACE-B trial comparing tereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately...

Hi there chap, We are on different paths I see from your stats. But you have to have some hope or there's no point in having treatment really. There is a nice man on Prostate UK who is refusing treatment (for now) as he cannot face the side effects. Brave chappy that he is. I'm just bloody hopeless with any drugs so didn't do well with the depression bit in the middle. But isn't time a healer as here I am on my 'orrible 'ormones hols and as near to 'normal' as I suppose I'll ever get. Bad thoughts and all that jazz almost a forgotten memory but I have to remind myself this is a holiday so one day I'll be following your path. I hope that once the effects of the chemo wear off into the sunset, you can have as normal a life as poss. All the be.

SAN FRANCISCO — A reduction to no circulating tumor cells at week 13 appeared to be a stronger indicator of survival outcomes than a 50% or greater reduction in PSA from baseline in phase 2 trials of metastatic castration-resistant prostate cancer, according to a study presented at Genitourinary Cancers Symposium.

We find ourselves in an interesting situation at the moment in the setting of M1 hormone-sensitive prostate cancer," said Davis, who explained that both docetaxel and abiraterone (Zytiga) have already shown substantial improvements in OS when added to ADT in this setting.

First-line enzalutamide, docetaxel combination improves disease control in advanced prostate cancer.

February 15, 2019 Among men receiving radiation therapy for prostate cancer, the proportion of those receiving brachytherapy dropped from 59.3% to 34.7% from 2004 to 2014, a study found.

Although tumor mutational burden is comparatively low in prostate cancer compared with other cancer types, researchers observed a significant association between higher tumor mutational burden and better outcomes in men with metastatic castration-resistant prostate cancer.

Doctors should share these results with men who get regular prostate-specific antigen (PSA) tests that screen for the presence of prostate cancer.

It was estimated that in 2018 alone, 165,000 men would be given a diagnosis of prostate cancer and more than 29,000 men would die from the disease.

Conditions : Breast Cancer; Prostate Cancer; Ovarian Cancer Interventions : Drug: Part 1, Dose Level 1 and Dose Level 2a: Ipatasertib; Drug: Part 1, Dose level 2b and dose level 3: Ipatasertib; Drug: Part 1, Dose Level 1 and Dose Level 2b: Rucaparib; Drug: Part 1, Dose Level 2a and Dose Level 3: Rucaparib Sponsor : Hoffmann-La Roche Not yet recruiting.

Study results showed that patients were unable to detect any difference in any of their symptoms or quality of life between treatments. Continue reading. →

Prostate cancer is considered metastatic once the cancer has spread outside of the prostate gland to other parts of the body.

For some reason prostate cancer patients are not tolerating therapy as well as the other populations," he said.

February 15, 2019 By targeting prostate-specific membrane antigen, a molecule radiolabeled with lutetium-177 is expected to deliver high doses of beta radiation to distant metastases.

New prostate cancer data puts Bayer drug in line with Pfizer, J&J rivals.

Karim Fizazi “These data are exciting for the prostate cancer community, as they show darolutamide’s potential to treat asymptomatic nmCRPC patients and delay spread of the disease,” said Karim Fizazi , professor of medicine at the Institut Gustave Roussy at the University of Paris Sud , France ...

Hi Joe, I'm not on any trial as far as I'm aware, I think the consultant would have said if I was and no I've not had radiotherapy. You read about people having all sorts of different treatments that you have never even heard of. May be it's a bit at a time treatment wise or if he doesn't need it don't give him it! Only time will tell, you just have to have faith in the consultant and hope he is doing his best for you. Cheers for now Keith.

Mentions

Hints:

Mentions

Food and Human Nutrition

Business Issues

Companies - Public

Companies - Venture Funded

Commodity Prices

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Information Technologies

Legal and Regulatory

Products - Animal

Products - Plant

Political Entities

Strategic Scenarios

Sources

Trends

Hints: